We Invite You To Join This Live Speaker Program Event

Nurtec ODT: A Flexible Option to Meet the Individualized Treatment Needs of Patients With Migraine

Enhance your knowledge of Nurtec® ODT (rimegepant) at this informative live presentation.

Presented By:
LISA HAMMARGREN KUYKENDALL, NP

Date and Time
Thursday, June 18, 2026
6:15 PM Pacific Time

Location
The Renaissance The Shore Room
1 South Lake Street
Reno, Nevada 89501
(775) 682-3900
Truckee Terrace

REGISTER NOW!

PLEASE RSVP FOR THIS EVENT BY CONTACTING:

McKayla Leggett: , mckayla.leggett@pfizer.com
Jocelyn Olsen: (775) 870-7487, jocelyn.olsen@pfizer.com

Kindly provide your full name, degree, specialty, address including state, and email address when registering, so you can be confirmed. Please also provide this Meeting ID# **INT-0094582** when you RSVP.

Because late arrivals may be prohibited from participating in the program, please make every effort to arrive by the designated start time. You are expected to remain for the duration of the program.

ODT, orally disintegrating tablet.

INDICATIONS

Nurtec ODT is indicated in adults for the:

- acute treatment of migraine with or without aura
- preventive treatment of episodic migraine

IMPORTANT SAFETY INFORMATION

Contraindications: Hypersensitivity to Nurtec ODT or any of its components.

Warnings and Precautions

Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue Nurtec ODT and initiate appropriate therapy. Serious hypersensitivity reactions have included anaphylaxis, dyspnea, and rash and can occur days after administration.

Please see accompanying full Prescribing Information.
Please see additional Important Safety Information for Nurtec ODT on the next page.

Nurtec® ODT (rimegepant)
orally disintegrating tablets 75 mg

IMPORTANT SAFETY INFORMATION (CONT'D)

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Nurtec ODT, in the postmarketing setting.

Monitor patients for new-onset hypertension or worsening of pre-existing hypertension and consider whether discontinuation is warranted.

Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Nurtec ODT.

If signs or symptoms of Raynaud's phenomenon develop, discontinue Nurtec ODT. Patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud's phenomenon should be monitored for and informed about the possibility of worsening or recurrence of signs and symptoms.

Adverse Reactions: The most common adverse reactions for Nurtec ODT vs placebo were nausea (2.7% vs 0.8%) and abdominal pain/dyspepsia (2.4% vs 0.8%).

Drug Interactions: Avoid concomitant administration of Nurtec ODT with strong inhibitors of CYP3A4 or strong or moderate inducers of CYP3A. Avoid another dose of Nurtec ODT within 48 hours when it is administered with moderate inhibitors of CYP3A4 or potent inhibitors of P-gp.

Use in Specific Populations: *Pregnancy:* It is not known if Nurtec ODT can harm an unborn baby. *Lactation:* The transfer of rimegepant into breast milk is low (<1%). *Hepatic impairment:* Avoid use of Nurtec ODT in persons with severe hepatic impairment. *Renal impairment:* Avoid use in patients with end-stage renal disease.

Please see accompanying full Prescribing Information.

Notice: Pfizer is committed to the appropriate marketing of its products to ensure that interactions with HCPs are professional exchanges designed to benefit patients and enhance the practice of medicine. All Pfizer-sponsored programs are conducted in accordance with PhRMA Code principles to address a bona fide educational need with appropriate attendees in a venue and manner conducive to informational exchange.

State and Federal Employees: State and federal laws and regulations may carry additional restrictions. By attending this event, you confirm that you have obtained any necessary approvals from your employer.

Public Disclosures: Pfizer reports payment and transfer of value data as required by federal and state transparency laws.

State Law Restrictions:

Minnesota: Regardless of where you practice or reside, if you are a Minnesota-licensed practitioner with prescribing privileges, then you may not consume any food or beverage associated with this event.

Vermont: Regardless of where you practice or reside, if you are a Vermont-licensed HCP, you may not consume any food or beverage associated with this event. Additionally, if you are an employee/agent of a Vermont HCP (e.g., PAs, non-prescribing nurses, etc.), regardless of where you practice or reside, you may not consume any food or beverage associated with this event.

Pfizer does not provide or pay for alcohol in connection with any Pfizer-sponsored program.

CGRP, calcitonin gene-related peptide; HCP, healthcare provider; PA, physician assistant.

This promotional program is for US healthcare professionals only.

Pfizer

Nurtec® ODT (rimegepant) orally disintegrating tablets 75 mg